Literature DB >> 8226987

Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease.

E Köpke1, Y C Tung, S Shaikh, A C Alonso, K Iqbal, I Grundke-Iqbal.   

Abstract

The major protein subunit of the paired helical filaments (PHF) of Alzheimer disease (AD) is the microtubule-associated protein tau. Tau is a family of phosphopolypeptides that are abnormally phosphorylated in PHF. In this study, a non-PHF pool of tau abnormally phosphorylated at Ser-199/202, and tau not phosphorylated at this site (AD P-tau and AD tau, respectively) were isolated from the 27,000 x g to 200,000 x g fraction of AD brain homogenate by extraction in 8 M urea, followed by dialysis against Tris buffer. AD P-tau and AD tau were further purified and separated from each other by acid precipitation, glial fibrillary acidic protein affinity chromatography, and phosphocellulose chromatography. The resulting AD P-tau and AD tau preparations were free of cytoskeletal proteins, ubiquitin, and beta-amyloid peptide. Immunochemical and morphological analysis of AD P-tau preparations revealed that most of the protein was of non-PHF origin. The AD P-tau was about 3-4-fold (approximately 8 mol P04/mol protein, M(r) 41,318) more phosphorylated than cytosolic tau from AD and control brains. Unlike PHF, the AD P-tau lacked ubiquitin. In AD brain the levels of cytosolic tau were about half of those in control aged cases. These findings suggest that the abnormal phosphorylation of tau in AD occurs in the cytosol.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8226987

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  220 in total

1.  Multiple forms of phosphatase from human brain: isolation and partial characterization of affi-gel blue binding phosphatases.

Authors:  L Y Cheng; J Z Wang; C X Gong; J J Pei; T Zaidi; I Grundke-Iqbal; K Iqbal
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

2.  Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner.

Authors:  Zhang Zhang; James W Simpkins
Journal:  Brain Res       Date:  2010-05-07       Impact factor: 3.252

Review 3.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

4.  Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects.

Authors:  Fabio Di Domenico; Rukhsana Sultana; Eugenio Barone; Marzia Perluigi; Chiara Cini; Cesare Mancuso; Jian Cai; William M Pierce; D Allan Butterfield
Journal:  J Proteomics       Date:  2011-04-13       Impact factor: 4.044

Review 5.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

6.  Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Alexander M Herman; G William Rebeck; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2011-09-14       Impact factor: 4.314

7.  The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines.

Authors:  Silvia Lisa; Massimiliano Meli; Gema Cabello; Ruth Gabizon; Giorgio Colombo; María Gasset
Journal:  Cell Mol Life Sci       Date:  2010-05-09       Impact factor: 9.261

8.  Monte carlo simulations of tau proteins: effect of phosphorylation.

Authors:  Y S Jho; E B Zhulina; M W Kim; P A Pincus
Journal:  Biophys J       Date:  2010-10-20       Impact factor: 4.033

Review 9.  Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.

Authors:  Filipa I Baptista; Ana G Henriques; Artur M S Silva; Jens Wiltfang; Odete A B da Cruz e Silva
Journal:  ACS Chem Neurosci       Date:  2014-01-03       Impact factor: 4.418

Review 10.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.